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Abstract
The outputs of R&D, such as new research findings and new products and
services are generated with the aid of specialized problem-solving processes. These
processes are somewhat arcane, and have been largely ignored in studies of technical
change. However, they represent an increasing proportion of economic activity, and can
affect the competitive positions of firms employing them.
In this paper we first describe the general nature of the trial-and-error problem-
solving processes and strategies for experimentation used in the development of new
products and services. We next discuss the rapid advances being made in problem-
solving methods, and the impact such advances can have on the competitive position of
adopting firms. Finally, we offer a detailed case study of the impact one novel
experimental method, combinatorial chemistry, is having on the economics of the drug
discovery process.
Keywords: Problem-Solving; Experimentation; Technological Innovation; R&D
Efficiency; Pharmaceutical Drug Development; Product Development
Performance.
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1. Introduction
The impact of outputs of the R&D process on firms and industries has long been
acknowledged. For example, the major consequences of the development and continued
improvement of semiconductors, of computerized manufacturing, etc. have been noted
by many. But the outputs of R&D are themselves "manufactured" with the aid of
specialized problem-solving processes. These underlying have been largely ignored in
studies of technical change. However, the application of problem-solving processes
represent an increasing proportion of economic activity (Carter 1995), and the processes
themselves are improving rapidly both in terms of the kinds and efficiencies of outputs
producible. These changes, in turn, are having and will increasingly have an impact on
the competitive position of adopting firms. Advancing our understanding of the
evolving economies of problem-solving as a result of dramatic technological and
methodological advances and their impact on R&D performance and strategy is the
purpose of this paper.
The structure of the paper is as follows. We begin (section 2) by describing
problem-solving via experimental trial and error used in R&D in general terms and
showing how different experimentation strategies can influence R&D efficiency. We next
(section 3) illustrate the rate of advance affecting experimental methods, and then
observe that early developers or adopters can have a competitive advantage over rivals,
because new methods are often difficult to acquire and use. We follow (section 4) by
presenting a field study of combinatorial chemistry - a new method now being
introduced into the drug discovery process that promises to make drug discovery both
faster and less costly. This case is especially relevant to our topic because more
effective drug discovery methods can convey a great competitive advantage to
pharmaceutical firms: Present drug discovery processes are currently very lengthy and
expensive, and the commercial advantages to being first with a significant new product
can be very large.
2. The Problem-Solving Process
Research into the nature of problem-solving shows it to consist of trial and error,
directed by some amount of insight as to the direction in which a solution might lie
(Baron 1988). This general finding is supported by empirical studies of problem-solving
in the specific arena of product and process development (Allen 1966, Clark and
Fujimoto 1988, 1991, Iansiti 1995, Marples 1961, Simon 1981, Smith and Eppinger 1997,
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von Hippel and Tyre 1995, Wheelwright and Clark 1992). Such studies show trial and
error learning conducted via a process of conscious experimentation as a prominent
feature. In this section we begin by discussing the general nature of problem-solving via
experimentation. Then we discuss the creation of strategies for solving a given problem
via a number of related experiments.
2.1. Problem-Solving via Experimentation
Problem-solving via experimental trial and error begins with the selection or
creation of one or more possible solutions. The alternatives selected may or may not
include the best possible solutions - one has no way of knowing. These are then tested
against an array of requirements and constraints (Dunker 1945, Marples 1961, Simon
1981). Test outcomes are used to revise and refine the solutions under development,
and - generally - progress is made in this way towards an acceptable result.
One may view the experimental trial and error process as consisting of a four-
step cycle: (1) one conceives of or designs an experiment; (2) one builds the (physical or
virtual) apparatus needed to conduct that experiment; (3) one runs the experiment; (4)
one analyzes the result (Thomke 1997a). For example, one might (1) conceive of and
design a new, more rapidly-deploying airbag for a car; (2) build a prototype of key
elements of that airbag as well as any special apparatus needed to test its speed of
deployment; (3) run the experiment to determine actual deployment speed; and (4)
analyze the result. If the results of a first experiment are satisfactory, one stops after
step (4). However if, as is usually the case, analysis shows that the results of the initial
experiment are not satisfactory, one may elect to modify one's experiment and "iterate" -
try again. Modifications may involve the experimental design, the experimental
conditions, or even the nature of the desired solution. (For example, a researcher may
design an experiment with the goal of identifying a new cardiovascular drug. However,
experimental results obtained on a given compound might suggest a different therapeutic
use, and cause researchers to change their view of an acceptable solution accordingly.)
The new information provided by a trial and error experiment to an experimenter
are those aspects of the outcome that he or she did not (was not able to) know or
foresee or predict in advance - the "error". Note, however, that any given experiment is
only designed to detect some types of error. Thus, in the example just given, the
apparatus designed to measure the speed of airbag deployment is unlikely to be able to
detect unanticipated toxicity in the gas used to inflate the airbag, even though
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information regarding this "error" would presumably be of great interest to the problem-
solver.
Experimentation is often carried out using simplified versions (models) of the
eventually-intended test object and/or test environment. For example, aircraft designers
often conduct experiments on possible aircraft designs by testing a scale model of that
design in a "wind tunnel" - an apparatus that creates high wind velocities that partially
simulate the aircraft's intended operating environment. The value of using models in
experimentation is twofold: to reduce investment in aspects of the real that are
irrelevant for the experiment, and to "control out" some aspects of the real that would
affect the experiment in order to simplify analysis of the results. Thus, airplane models
used in wind tunnel experiments generally include no internal design details such as the
layout of the cabins - these are both costly to model and typically irrelevant to the
outcome of wind tunnel tests, which are focused on the interaction between rapidly
moving air and the model's exterior surface.
Models used in experimentation can be physical as in the example just given, or
they can be represented in other forms. Computer simulation, for example, involves
representing experimental objects and experimental environments in digital form, and
then simulating their interaction within a computer in a type of virtual experiment.
Thus, one might model an automobile and a crash barrier inside computer, perform the
computations needed to simulate the crash of the model car into the model barrier, and
then calculate the effects of that crash on the structure of the car via finite element
analysis. One could then assess the results of this virtual experiment by viewing a visual
display of the "crashed" car on a video display, and/or by looking at detailed
calculations of the forces and accelerations generated during the simulated crash and the
effects of these on the car's structure.
Sometimes designers will test a real experimental object in a real experimental
context only after experimenting with several generations of models that isolate different
aspects of the real and/or that encompass increasing amounts of the complexity of the
real. Developers of pharmaceuticals, for example, might begin by testing a candidate
drug molecule against just the purified enzyme or receptor it is intended to affect, and
then test it again and again against successively more complex models of the human
organism (e.g., tissue extracts, tissue culture, animal models, etc.) before finally seeking
to test its effect on real human patients during clinical trials.
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Models do not represent reality completely (if they did, they would be the reality
they are to represent). In part this is by design, and for the purposes mentioned earlier.
In part the representation is incomplete because one does not know and/or cannot
economically capture all the attributes of the real situation, and so could not transfer
them into a model even if one wanted to. The incompleteness of a model is a source of
unexpected errors when a given model being used in testing is replaced by a different
model or by the real context or object for the first time (Tyre and von Hippel 1997). As
an illustration, consider the airbag inflation example given earlier. If the gas used to
inflate the airbag had been toxic, and the various experimental apparatus used to test
the airbag had not been capable of detecting this factor, the problem would have been
detected as an unexpected error only when real airbags were deployed in the real use
environment.
2.2. Strategies for Experimentation
Researchers engaging in problem-solving via experimentation generally do not
expect to solve a problem via a single experiment, and so often plan a series of
experiments intended to bring them a solution to their problem in an efficient manner.
The strategy they choose is in part a function of the information they already have
regarding the topography of the "fitness landscape" upon which they will seek a
solution for their problem. The concept of a "fitness landscape" comes from the study
of evolutionary biology and refers to the distribution of fitness values across a space of
entities (Kauffman and Levin 1987, Wright 1932). More recently, fitness landscapes
have been used in the study of organizational structure and strategy in the context of
changing environments (Bruderer and Singh 1996, Levinthal 1997).
In practice, real-world experimenters may not have much information regarding
the fitness landscapes relevant to their work. (Studies in an analogous field -
explorations of the specification of well-structured problems - have shown the difficulty
of obtaining such information. l) Nonetheless expectations regarding the topography of a
1 Well-structured problems are defined as those for which one can precisely specify a process of
trial-and-error that will lead to a desired solution in a "practical" amount of time (Reitman
1965, Simon 1973, Pople 1982). For example, a traveling salesman problem "of a size
amenable to practical computation" is well-structured, because one can precisely specify a
generator of alternative solutions and solution testing procedure that are guaranteed to
eventually identify the best solution. However, "In general the problems presented to
problem-solvers by the world are best regarded as ill-structured problems. They become well-
structured problems only in the process of being prepared for the problem-solvers. It is not
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fitness landscape are very relevant to the construction of efficient experimental
strategies. We can illustrate by reference to the choice between a strategy of serial
experimentation versus parallel experimentation. Consider that, when identification of
a satisfactory solution to a problem involves more than one trial and error experiment,
the information gained from a previous experiment(s) may serve as an important input
to the design of the next one. Experiments which do incorporate learning derived from
other experiments in a set are considered to have been conducted in series. Experiments
that are conducted according to an established plan that is not modified as a result of
the finding from other experiments are considered to have been conducted in parallel.
For example, one might carry out a pre-planned "array" of experiments, analyze the
results of the entire array, and then carry out one or more additional verification
experiments (Montgomery 1991). The experiments in the initial array are viewed as
being carried out in parallel, while those in the second round are carried out in series
with respect to that initial array.
Suppose that the problem at issue is to deduce the correct combination for a
combination lock. Good locks may have 106 or more possible combinations, of which
only one is correct. They are also designed so as to give an "experimenter" (in this case,
a robber) no indication as to how close he or she may be to the correct combination.
That is, they are designed to display a fitness landscape that is absolutely flat for all
combinations except the correct one, which can be visualized as rising up from the
landscape like a narrow tower with vertical sides. In a fitness landscape with this
topography, a parallel experimentation strategy would be the fastest, although not
necessarily the most efficient choice (see table 1, and related discussion below). This is
because, in this landscape configuration, each failed trial provides very little information
that would be of use in a serial experimentation strategy - only the information that "the
combination you just tried is not the correct one."
In contrast, suppose that the fitness landscape is a hill with only a single peak
and sides that extend to all edges of the landscape. (This is the shape, for example, of
the fitness landscape in the children's' game in which a child is guided to a particular
spot via feedback from other children who say "warmer" each time a step is taken
towards that spot.) In such a case a strategy of serial experimentation may be the most
efficient choice, because the information gained from each step taken is so useful in
exaggerating much to say that there are no well-structured problems, only ill-structured
problems that have been formalized for problem-solvers." (Simon 1973 p. 186)
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guiding the direction of the next trial step that the correct solution is often found after
only a few trials.
The relative efficiency of experimentation strategies can be estimated using what
is known about the topography of the solution space, and what is known about the time
and money costs associated with designing, building, running and analyzing an
experiment. Consider the following simple example in which the topography of the
fitness landscape is known to consist of n points and to have the configuration
described in the lock example discussed above - flat except for a single point
representing the correct solution.
Experi-
mentation
Strategy
Learning from
Experimental
Trials
Expected # of
Experiments (X)
Expected Cost
(C)
Expected Time
(T)
(a) Parallel
Experimentation
Run Experiments
me_1F_2 . [a
_7~ ·
Screen Solution
i i i . i i
- None.
E[X] = n
n x [Ctrial + Cscreen ]
Ttrial + Tscreen
(b) Serial
Experimentation
(Minimal Learning)
- Eliminate un-
successful trials.
n+l
E[X] =+2
n+l
-X [Ctria + Cscre] ]
2
n+l
x [Ttria + Tscree]
2
(c) Serial
Experimentation
(With Learning)
- Eliminate
unsuccessful trials.
- Intelligently select
next trials.
•<X• n+l
2
X X [Ctrial + Cscreen ]
X x [Ttrial + Tscreen ]
Table 1. A comparison of different experimentation strategies2 (for a proof of (b),
see appendix A). Massively parallel experimentation is particularly beneficial if the
value of time is high relative to the cost of an experiment.
2 In "serial experimentation with minimal learning", running a given experiment will only
indicate whether a point tested in an experiment is a correct solution or not. No information
as to which of the still untested points should be tested next will be provided - thus we have
to select the next point to be tested randomly. An unsuccessful experimental trial therefore
i
! ii
- ._
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A pure parallel experimentation strategy (strategy (a) in table 1) would require
all experiments and their analysis to be done at the same time. Thus, one would not be
able to incorporate what one has learned from one trial and apply it to the next trial.
While this approach results in a very high number of experiments, it also reduces the
total development time significantly as all experiments are done in parallel. Thus, in the
case of this example, massively parallel experimentation would be the costliest but also
the fastest strategy.
In contrast, a serial strategy applied to this sample problem would allow one to
learn from each experimental trial and intelligently select the next one. As shown in
table 1, a strategy even with minimal learning (i.e. not repeating a trial that has failed)
can halve the total number of experiments required on average, but would dramatically
increase total development time relative to the purely parallel approach (strategy (b) in
table 1). Of course, if there is the opportunity for greater learning from each trial, the
number of trials in the series likely to be required to reach the solution (and therefore the
total elapsed time) is further reduced (strategy (c) in table 1). For example, consider a
scenario where the n trials are arranged on a linear scale (e.g. n different pressure
settings) and that after each trial, one could learn whether to move up or down on that
scale. Presumably, an experimenter would start with n/2 (the midpoint) and move to
either n/4 or 3n/4, depending on the outcome of the first experiment, and continue in the
same fashion until the solution space is exhausted. It can be shown that the expected
number of trials until success using such a serial strategy (with the kind of learning
described) can be reduced to log2n - a dramatic reduction in cost. However, total
development time would exceed that of the purely parallel strategy by the same factor.
Real-world experimentation strategies can be much more complex than our
simple example, and will often contain a combination of serial and parallel approaches.
3. Advances in Experimentation and Problem-Solving - and the Impact
on Firms
The methods and tools available to help solve many types of problems are
rapidly changing and improving. These advances are affecting all of the elements of the
merely allows us to reduce the search space by one and therefore it increases the probability
of success during the next trial. In "serial experimentation with learning", running an
unsuccessful experiment does provide guidance on how to run the next experiment. Therefore,
the expected number of trials until success can be significantly less than the "minimal
learning" case.
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experimentation process that have been described in the previous section. That is, they
are rapidly reducing the cost and time involved in designing and executing and analyzing
many types of experiments, and are also affecting the type of experimentation strategies
that may be most effective for an experimenter. In this section we first illustrate the
rapid advances being made in experimental methods by noting the rapid evolution of
experimentation via computer simulation. Next we will discuss the impact that such
advances can have upon the competitive position of firms.
3.1. Advances in Methods for Experimentation and Problem-Solving
There is no general index that documents the rate of advance in problem-solving
methods and tools. However, those with a professional interest in these matters
generally judge that the rate of change today is very rapid. Advances in some fields,
such as computer simulation, are applicable to a wide variety of subject matter. Others
such as the scanning tunneling electron microscope are germane to only a narrow range of
applications - although the range of application seen for a given technique often
broadens significantly over time (Rosenberg 1982). The reader may find a brief overview
of the rapid evolution of computer simulation techniques to be a useful way to gain a
feeling for what we mean by "rapid advances in methods and tools" in the case of a
generally-applicable tool. Later, in section four, we will provide a detailed description
of the nature of and impact of an advance with a narrower range of application -
combinatorial chemistry.
As was noted earlier, experimentation via computer simulation involves
representing experimental objects and experimental environments in digital form, rather
than in the form of physical objects tested within physical environments. Then, their
interaction is within a computer in a type of virtual experiment. The advantages of
substituting virtual experimentation via computer for experimentation with real physical
objects can be very significant. For example, studying automobile structures via real car
crashes clearly is quite expensive and time-consuming - a crash prototype can cost in
excess of one million dollars and may take up a year to build and test. In contrast, once
the proper digital models have been created, a virtual car crash can be run again and
again within a computer under varying conditions at very little additional cost per run.
Further, consider that a real car crash experiment happens very quickly - so quickly that
the experimenter's ability to observe details is typically impaired, even given high-speed
cameras and well-instrumented cars and crash dummies. In contrast, one can instruct a
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computer to enact a virtual car crash as slowly as one likes, and can zoom in on any
structural element of the car (or minute section of a structural element) that is of interest
and observe the forces acting on it and its response to those forces "during" the crash.
Thus, computer simulation may not only decrease the cost and time of an experimental
cycle but can also increase the depth and quality of analysis, leading to improved
learning and ultimately products of higher quality (Thomke 97b).
The steady (and really quite spectacular) improvement in the capabilities of
digital computers over the past few decades has made it possible and desirable to carry
out more and more experiments via computer simulation, rather than via physical
experimentation (see figure 1).
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Figure 1. Growth of computer technology since 1955, showing advances in average
commercial performance and milestone events (from Brenner 1996). Problems that
are solvable in reasonable times at the indicated level of computer performance are
shown in brackets. Approximate system prices are shown in dollars of the time.
Computer simulation is today being used as a substitute for or supplement to
physical experimentation in fields ranging from the design of drugs (e.g., rational drug
design) to the design of mechanical products (e.g., finite element analysis), to the design
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of electronic products (e.g., computer simulation of digital circuitry) to the analysis of
global warming (e.g., climate modeling). The ability to usefully substitute a simulation
for a "real" experiment requires, of course, more than the development of advanced
computer equipment. It also requires the development of simulation models that are
accurate from the point of view of a given experimental purpose. Often, a simulation
model will not be fully accurate in ways that later turn out to matter. When this is
recognized, virtual and physical experiments may be conducted in some combination in
order to combat this source of error. (For example, auto designers will supplement data
gathered from virtual car crash experiments with data from real crash experiments using
real cars, in order to assure themselves that the results of the virtual experiments also
hold in the real world.)
At the same time, of course, methods for conducting physical experiments are
also advancing. For example, significant advances are being made in reducing the costs
and time of building the various types of prototypes. Complex three-dimensional
objects used to require days or weeks of work in a machine shop to fabricate. Many such
shapes can now be made rapidly - in very few hours - by using computer-controlled
machining equipment and/or equipment for creating objects via "three dimensional
printing" (Sachs 1992). Similarly, physical prototypes of complex electrical circuitry -
custom integrated circuits - used to take months to create via "full custom" methods, and
weeks to create via "Application-Specific Integrated Circuits" (ASIC) technology
(Einspruch and Hilbert 1991). Now, designers can create customized circuits in minutes
at their desks or lab benches using so-called "Field Programmable Gate Arrays" (FPGAs)
(Villasenor and Mangione-Smith 1997).
3.2. Impact of Changes in Experimental Methods on Firm Competitiveness
The adoption of more effective experimental methods for problem-solving and
the development of new products and services, such as those just described, can lead to
significant competitive advantages for adopting firms relative to rivals if novel
techniques that offer such advantages are not rapidly picked up by rivals as well. Or,
as Barney (1986) and Wernerfelt (1984) put it with respect to core competencies: a core
competence can be a source of long-term competitive advantage for a firm if it is difficult
or impossible to buy or sell in the available factor markets, and if it is difficult to
replicate.
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We argue that the new and more effective experimental methods and techniques
that are rapidly emerging are indeed often difficult to buy and sell, and difficult to
replicate as well, and therefore that they can and do serve as a significant source of
long-term competitive advantage for innovators and early adopters. The reason that
this is so is that new methods require (1) the transfer of significant amounts of new
information to the adopting firm, including new skills, and (2) some reorganization of a
firm's R&D activities as well.
The requirement that new information must be transferred to a firm adopting a
new experimental technique is in itself a barrier to adoption in many instances, because
information is often costly to transfer to a new site in a form usable by a given
information seeker. Transfer costs are affected by attributes of the information itself (e.g.
how the information is encoded), and also by attributes of and choices made by
information seekers and information providers (Arora and Gambardella 1994, Cohen
and Levinthal 1990, Griliches 1957, Mansfield 1968, Nelson 1982, Pavitt 1987,
Rosenberg 1982, Teece 1977, von Hippel 1994). Thus, consider that part of the
information associated with the ability to execute new experimental methods may be
embodied in equipment that can be purchased and installed by an adopting firm - a
relatively easy form of transfer. For example, a firm can buy computers and computer
programs that can be used to do experiments via computer simulation.
But new equipment and new software provide only a portion of the information
a firm needs to actually become competent at performing a new experimental method.
Typically, new skills and expertise are also needed and, as Polanyi has pointed out,
skill and expertise are often encoded within an expert's mind as tacit information that is
difficult to transfer to another. Thus, he notes that "the aim of a skillful performance is
achieved by the observance of a set of rules which are not known as such to the person
following them" (Polanyi 1958). For example, swimmers are probably not aware of the
rules they employ to keep afloat, e.g., in exhaling, they do not completely empty their
lungs, nor are medical experts generally aware of the rules they follow in order to reach a
diagnosis of various symptoms. And, as Polanyi reasons, "an art which cannot be
specified in detail cannot be transmitted by prescription, since no prescription for it
exists. It can be passed on only by example from master to apprentice..." - a relatively
time-consuming and costly mode of transfer.
Adopting novel experimental methods also often requires considerable change on
the part of organizations. As Morison (1966) and Sch6n (1967) have pointed out,
Page 12
Modes of Experimentation: An Innovation Process - and Competitive - Variable
organizations are often built up around and adapted to existing technologies. When this
is so, changes in technologies may require changes to organizational structures and
routines.
As an illustration, suppose that a firm wishes to replace some physical
experimentation methods being carried out in its labs with computer simulation
methods. To do this, it must typically hire new kinds of people and also reorganize the
relationships between the various specialists who jointly carry out the experiments. In
its existing organizational arrangements designed for physical experimentation, for
example, the firm might have routines in place that enable researchers to work with
design engineers and modelmakers to design and build the experiments that they wished
to run. Next, the procedures might dictate that the completed experimental apparatus
be transferred to experts at specialized test facilities who would actually run the
experiments, collect the resulting data, and then supply that data to the researcher for
analysis. In contrast, experimentation via computer simulation would require quite
different organizational routines. In some cases these would enable the researcher to do
the entire design, build, test and analyze experimental cycle in his or her own lab. In
other cases, they might facilitate collaborative arrangements between the researcher and
various types of experts not previously employed by the firm who specialize in different
aspects of computer simulation.
With respect to the difficulty of achieving such organizational change, we note
that Holmstrom and Tirole (1991) have argued that organizational arrangements cannot
serve as sources of enduring competitive advantage because they can be easily
replicated. However, much of the literature on organizational change suggests otherwise.
Thus, Henderson and Cockburn (1994), in a study of cardiovascular drug discovery,
report that organizational capabilities found associated with improved productivity at
this type of research task are in fact often very difficult to transfer from firm to firm 3.
3 Henderson (1994: 624-6) illustrates difficulties associated with replicating organizational
capabilities associated with better performance at drug discovery by presenting examples
experienced by firms in their sample. Thus, there was a period when leading-edge drug
discovery processes were shifting from simple mass screening of compounds for possible
medicinal effects to a more precise form of research based on an understanding of a drug's
mechanism of action. This change was being driven by the academic research community.
Drug firm "Alpha," which had long-term ties to the academic community and which
employed leading-edge researchers who were accepted as peers in that community, had no
difficulty in quickly adopting the new approach to drug discovery. In contrast, firm Beta,
which had not had a practice of employing scientists known to and respected by the academic
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Further, they note that such arrangements can have an important impact on research
productivity. In their study, about 30% of the observed variation in the "productivity"
of firms in drug discovery (number of drugs discovered per R&D dollar invested) was
due to unique organizational capabilities (represented by a variety of measures such as
to the degree to which the firm actively manages the integration of knowledge across
disciplinary and firm boundaries).
4. Field Study: The Impact of New Drug Discovery Methods on
Pharmaceutical Drug Development
To this point we have described the nature of problem-solving via
experimentation in R&D, have observed that methods for accomplishing this task are
evolving rapidly, and have argued that competence at problem-solving via
experimentation can be important with respect to the competitiveness of firms that
perform R&D. In this section we develop these points further via a case study of a
recent improvement in experimental methods used in the drug discovery process -
"combinatorial chemistry". We begin by describing the serious drug development
problem currently facing pharmaceutical firms. Next, we describe the drug discovery
process. Then we describe combinatorial chemistry, and finally we describe a research
project that clearly illustrates the impact that this new method can have on the drug
discovery process - and with it, upon the competitiveness of pharmaceutical firms.
4.1. The Product Development Problem Facing Pharmaceutical Firms
If improvements in problem-solving methods are important to any firm, they
should certainly be important to firms in the pharmaceutical industry. On the one hand,
pharmaceutical firms face many potentially profitable opportunities to create new drugs
to cure or ameliorate diseases ranging from cancer to heart disease, particularly if firms
manage to receive patent protection and reach the market before their competitors do.
Markets for new drugs typically involve $50-400 million in annual sales, and can reach
sometimes into the billions as in the case of Zantec, a stomach acid inhibitor drug for
ulcer treatment. On the other hand, the drug development process is currently one' of the
most time-consuming and costliest product development processes in any industry.
community, found it very difficult to make the change. For example, they found it difficult to
hire "better" people from academia who were experts in the new approach, because they did
not have a reputation as a leading-edge place to work.
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A widely-cited study of pharmaceutical drugs developed between 1972 and
1987 found that the expected capitalized development cost per marketed drug was on
average 230.8 million (1987) dollars (DiMassi et. al. 1991), with total development times
well above ten years. Various other studies have shown a trend that has caused much
concern in the pharmaceutical industry: the cost and time of new drug development has
increased significantly over the last thirty years (e.g. DiMassi et. al. 1994). Besides the
impact of lower R&D productivity on firm cost and profitability, longer development
times have also raised important public policy concerns. As the industry remains the
dominant provider of life-saving and life-prolonging medicines, it is in the public interest
to have promising new drugs available to patients as quickly as possible (Savello 1996).
The complete drug development and approval process involves three phases. It
begins with a "preclinical" research phase devoted to the discovery and optimization of
one or a few "lead" chemical compounds that appear to hold sufficient promise as drugs
to merit investment in clinical testing. The second phase, clinical development, consists
typically of three clinical phases to determine and document the safety and efficacy of
the proposed drugs. The final phase involves regulatory New Drug Approval (NDA)
review processes of the clinical trial outcome. The average cost and duration of
preclinical and clinical development for drugs developed between 1972 and 1987 is
provided in table 2.
Uncapitalized Mean phase Capitalized
Testing Phase'1 expected cost length (months) expected cost 2)
Preclinical 65.5 42.6 155.6
Long-term animal 5.3 33.6 8.2
Other animal 0.4 33.6 0.7
Phase I 9.3 15.5 17.8
Phase II 12.9 24.3 21.4
Phase III 20.2 36.0 27.1
Total 113.6 230.8
(1) The New Drug Approval (NDA) review period was estimated to last 30.3 months.
(2) Costs were capitalized at a 9% discount rate.
Table 2. Expected phase costs per New Chemical Entity (NCE) (in millions of
1987 dollars) (from DiMasi, Hansen, Grabowski and Lasagna 1991)4.
4 All costs were deflated using the GNP Implicit Price Deflator. A 23% clinical approval rate
was utilized.
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4.2. The Drug Discovery Process
Drugs achieve their effect by binding with very specific molecular receptors or
enzymes or biologically important molecules that are present in the human body or
on/in disease-causing agents such as bacteria, fungi and viruses. The goal of drug
discovery or drug design is therefore to discover or create a molecule that will in fact
bind to a particular, say, receptor with a required degree of tenacity (binding affinity),
and that will at the same time not bind to other receptors that may be structurally
similar but have different functions.
The drug discovery process can involve either or a combination of two basic
approaches:
(1) One can start with little or no knowledge about the structure of a disease target
(receptor, enzyme, molecule) associated with a particular disease, and simply try
out many candidate molecules until one finds one that happens to bind properly
with the target receptor.
(2) One can strive to determine the structure of the relevant receptor with biophysical
methods, and then attempt to design or select a molecule that will bind to it.
Until the 1970's methods of drug discovery necessarily relied on the first of these
two approaches because the technical ability to determine the molecular structure of a
protein receptor did not yet exist. Researchers at early pharmaceutical firms (often
subsidiaries of chemical manufacturing firms) implemented this approach by setting up
a systematic trial and error drug discovery system known as the "mass screening"
system, which is still used today.
The mass screening system begins with the selection or design of a "screen" - e.g. a
disease-causing bacterium or an isolated receptor that is known to be associated with
the disease under study. "Masses" of chemical compounds are then applied to this
screen (one at a time), with the goal of identifying compounds that cause the screen to
display a desired effect (e.g., killing of the disease-causing bacterium; evidence of
binding to the receptor).
Traditionally, there have been two different sources of input materials to the
mass screening process. The first source is proprietary archival libraries of known
chemical compounds that have been collected by chemical and pharmaceutical firms
over the years. A given major firm might have an archival library of perhaps half a
million known compounds. The second source is extracts of plants, microorganisms and
Page 16
Modes of Experimentation: An Innovation Process - and Competitive - Variable
animals, each of which may contain perhaps up to 100,000 unknown chemical
compounds.
Mass screening proceeds differently depending on which type of input is used.
In the case of archival libraries, the known compounds are tested against the disease
target screen one by one, and the effect of each on the screen is observed. In the case of
natural extracts, the entire extract is tested against the screen. If a desired effect is
observed, the compound responsible for that effect must then be isolated via a complex
series of fractionations and retestings.
As an illustration for the natural compound process, consider the development
of antibiotics based on "magainins." When researchers noticed that frogs living in
bacteria-contaminated water did not appear to get skin infections, they suspected that a
new and useful antibiotic compound in a frog's skin might be involved (Zasloff 1987).
To identify it, they began by grinding up frog skin and subjecting the whole mixture -
consisting of literally hundreds of thousands of different compounds - to mass screening
tests for antibiotic activity. When these tests did indicate antibiotic activity, they next
had to identify which compound(s) in the complex mixture was (were) the source of that
activity. This was done by biochemical separation of the compounds found in frog skin
into fractions, followed by a test of each fraction for the presence of antibiotic activity.
The active fraction was then subject to further cycles of fractionation and test until
finally the active compound was isolated.
When an active compound is finally identified via mass screening, it will
generally not meet all of the criteria required to make it a "lead" candidate for a new
drug. For example, it may display the needed medical effect very powerfully, but at the
same time may display unacceptable side effects such as toxicity, mutagenic effects in
animals, or may not become available in the bloodstream after ingestion or injection
Therefore, the lead optimization process in the drug discovery process is to create and
test a number of variations ("analogs") of the originally-identified molecule, in order to
find one or more that appears to have all the attributes needed for a successful new
drug. One lead compound is then advanced into the clinical development phase where
its effects are tested on humans.
At this point we should note that the traditional process used to create analogs
to a proposed drug in order to create a lead drug compound is typically a very costly
and time-consuming matter. In order to create analogs to the original compound,
medicinal chemists (specialized organic chemists employed by pharmaceutical firms)
Page 17
Modes of Experimentation: An Innovation Process - and Competitive - Variable Page 18
maintain the basic structure of that compound, but add, exchange or remove chemical
groups from it. On average it takes 7 to 10 days and approximately $7,500 to
synthesize one such analog (Longman 1994). According to the statistics of the Centre
for Medicines Research the average American pharmaceutical company synthesizes
approximately 6,100 chemical compounds for each successful drug that makes it to the
market place (Halliday, Walker and Lumley 1992b). This amounts to an average of $46
million for analoging alone, with a total time requirement of 170 man years.
The reason it is necessary to develop so many potential solutions to the receptor
problem is because many drugs must be precisely tailored to discriminate sharply
between very similar receptors. For example, researchers working to develop a drug for
Alzheimer's disease are targeting a particular muscarinic receptor located in the brain.
However, five subtypes to this muscarinic receptor are known to exist in the gut and
elsewhere, and the desired drug must not affect these. Compounds displaying the
needed selectivity can be very difficult to find without extensive analoging.
4.3. Rational Drug Design versus Combinatorial Chemistry
In this century, the knowledge in chemistry, biology and the molecular basis of
disease has increased exponentially. In the beginning of the 80s advanced methods of
protein structure determination and computer supported molecular modeling became the
focus of the pharmaceutical industry. This new technology was thought by many in the
industry to be sufficiently advanced to allow the creation of a "rational drug design"
methodology as an alternative to the traditional approach to drug discovery.
Pharmaceutical researchers using the rational drug design approach would use x-
ray crystallography and/or nuclear-magnetic resonance (NMR) spectroscopy to
determine the three dimensional shape of a receptor or an enzyme that they wish to
influence with a drug. They would then enter the structure of this receptor into a
computer software package containing information on the configuration and strengths of
the chemical bonds that can form between atoms. This software would then allow them
to use simulation to design drug molecules that bind properly to the target receptor.
Real molecules would then be created by chemists in the laboratory as specified by the
computer modeling exercise, and these would be tested for the desired pharmaceutical
effect. Thus rational drug design is an example of a strategy that tries to maximize the
amount of learning between trials and thereby achieve a total reduction in the number of
experimental trials (as explained in table 1, strategy (c)).
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However, the "rational" approach to drug design has proven to be problematic
for two reasons. First, the molecular modeling of a drug requires very accurate data on
the structure of the target receptor, and the required degree of accuracy is often very
difficult for researchers to attain using present-day methods. Second, it has been found
that the shape of a target receptor can change dramatically when a drug is inserted into
the receptor's "binding pocket" (see figure 2). The effect of such "induced fit" shape
changes is that a drug that has been designed to fit a receptor's empty binding pocket
may in fact not fit at all. Induced fits between receptor and drug are too complex to be
modeled by present computer simulation tools. As a consequence, rational drug design
has proven not to be a full replacement for traditional drug design methods. Instead,
computer-based molecular modeling exercises prescribed by the rational drug design
procedure are still followed up by medicinal chemists who create and test analogs to the
rationally-designed compound, just as was done in traditional drug development.
Figure 2. Illustration of dramatic structural alterations to the binding
pocket of a receptor resulting from insertion of a drug molecule (from
Stryer 1995).
In the last few years, a new method called "combinatorial chemistry" has
emerged very rapidly (figure 3), primarily due to its impact on the underlying
experimentation economies (Plunkert and Ellman 1997). Combinatorial chemistry
makes the synthesis of proposed drug compounds and analogs radically faster and
cheaper (the basic principal of combinatorial chemistry and the underlying process
technologies are described in appendix B). For example, cost reductions from about
$7,500 per compound (traditional medicinal chemistry) to perhaps $1 to $10 per
compound have been reported, with reductions in preparation time of comparable
magnitude. Where a skilled medicinal chemist requires 7 to 10 days to create a single
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analog using traditional methods, a chemist can now use automated equipment and
combinatorial chemistry techniques to create thousands of analog compounds - each
precisely identified by an attached chemical "tag" - in a matter of days (Franke 1995).
Thus, as we will see in the following section, the dramatically different economies of
combinatorial chemistry are inducing drug developers shift to mixed experimentation
strategies with a strong emphasis on massive parallelism, while at the same time
reducing total development time dramatically (as was explained in table 1, strategy (a)
and related text).
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Figure 3. The rapid increase of scientific publications on combinatorial chemistry
(source: Science Citation Index which covers 90% of the world's significant
scientific and technical literature).
The impact of this new capability on the drug discovery promises to be very
significant. The amount of information that must be acquired about the structure of a
receptor via computer modeling, crystallographic studies, etc. can be greatly reduced
with the application of combinatorial chemistry methods, because these can be used to
create literally hundreds or thousands of compounds that might fit the receptor. The
most promising (that is, the ones with the best desired influence on the target receptor)
can then be identified via a mass-screening process. Next, one can create a new library
of hundreds or thousands of analogs for each of these "round one winners" within a few
days or weeks. One can then repeat this screening, selection and analoging process until
one gets compounds displaying an excellent level of binding to only the target receptor.
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Because one has been able to create and test so many analogs, one can generate a "lead"
compound more quickly and more cheaply. And, perhaps even more important, one can
identify a better lead compound to carry forward into the very expensive clinical
development phase.
4.4. Case Study: Drug Discovery at Pharmacopeia via Combinatorial Chemistry
Methods
We next illustrate the impact combinatorial methods can have on the economics
of the drug discovery process by describing a research project carried out by
Pharmacopeia Inc. of Princeton, New Jersey. Pharmacopeia is a well-known leader in
the novel field of combinatorial chemistry using solid support libraries (see appendix B).
We compare the costs and outcomes that were achieved by using combinatorial
chemistry in this case versus estimated costs and outcomes that would have been
achieved by using more traditional methods. We find that traditional methods would
have been dramatically slower and costlier in this case - and would probably only have
produced "lead" drug candidates with little chance of clinical success.
The drug discovery project we report upon deals with the identification of lead
drug candidates to be used in the treatment of an important eye disease ("glaucoma")
that affects 1 in 100 adults. Glaucoma is a wide-spread human disease responsible for
impaired vision and eventual blindness. To document this project, we interviewed
Pharmacopeia's leading scientists and executives. These interviewees provided us with
information about Pharmacopeia's combinatorial chemistry technology in general and
detailed information on a drug development case in particular. Personal interviews were
followed with a detailed questionnaire that provided us with data on the efficiency of
the drug discovery process used in this project. (For detailed description of the
underlying chemistry used, see Burbaum et. al. 1995.)
Glaucoma is caused by a build-up of pressure within the human eye which in
turn causes damage to optical nerve cells. Scientific research has shown that excessive
pressure can be treated with the aid of what is known as the "diuretic" effect (a
reduction of liquid causes a decrease in pressure). It is also known that a certain group
of drugs - known as carbonic anhydrase drugs - can precisely cause this diuretic effect,
leading to stabilized pressure within the eye and long-term preservation of vision. The
glaucoma project's objective was to find sulfonamide compounds that "lock" into and
inhibit the function of the human carbonic anhydrase enzyme (hCAI) which regulates the
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production of liquid in the human eye, thus leading to a reduction of both, pressure and
damage to optical nerve cells. As it is usually the case with pharmaceutical drugs, a
promising lead compound had to discriminate against enzymes that have very similar
structures in order to avoid unacceptable side effects.
Figure 4. Each of the points represents a compound tested. The abscissa
and ordinate indicate the affinity of the compounds for the human and
bovine isozyme respectively. Note that, from the large number of compounds
screened only three compounds per receptor (shown as large squares)
displayed the desired discriminatory capability.
In Pharmacopeia's case, a promising lead compound that might guide the way to
an eventual new drug had to interact with hCAI, but discriminate against the bovine
isozyme (bCAII) - two very similar receptors. (The bovine isozyme acts as a starting
model for hCAII which is the human isozyme; once a drug that discriminates against
bCAII is found, it acts as an excellent lead for discrimination against the human isozyme
hCAII.) The sulfonamide compounds identified served as leads for additional phases in
the drug development process. Identifying suitable lead compounds was very difficult
because, as was learned later, only three compounds out of thousands tested eventually
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displayed the searched-for selectivity. (See figure 4; only compounds close to the
abscissa and ordinate can discriminate against the respective enzymes.) Failure to
discriminate against enzymes other than hCAI, however, was known to cause serious
side-effects such as difficulties in breathing, convulsion, muscle cramps, and trembling.
R&D Efficiency of Combinatorial Chemistry versus Traditional Drug Discovery
Methods
Lead compounds for the glaucoma project were identified using the
combinatorial chemistry methods we described earlier. Data on development time, cost
and experimentation strategies was collected for the actual mode used (combinatorial
chemistry) and a hypothetical case using traditional medicinal chemistry was
constructed (table 3).
Table 3. Comparing combinatorial chemistry with traditional medicinal chemistry
in the discovery of promising lead compounds for the treatment of glaucoma.
Combinatorial Traditional
Project Variable Approach Approach (l)
(1) Total development time 3.5 months 5 years (2)
(2) No. of chemists needed 4 15 (2)
(3) No. of compounds tested - 9000 ~3750 (3)
(5) No. of (serial) rounds 1 (4) 100 (250 max.) (5)
(6) No. of compounds per round - 9000 -38
(7) Cost of screen per round $10,000 $10,000
(8) Total cost (chemists only) (6) $167,000 $18.75 Mill.
(9) ...per compound $19 (7) $5000
(1) Based on estimates from developers very experienced with medicinal drug
development.
(2) Typical time and resources planned for a project of the given complexity and
strategic importance.
(3) A skilled chemist can prepare 50 compounds per year.
(4) During a short second round, 220 compounds were prepared over a 2-week period.
The compounds were a subset of the first round and did not contain new members.
(5) While 250 is theoretically possible, it doesn't allow sufficient time for learning
and analysis between rounds. Thus 100 rounds is a realistic number.
(6) A skilled chemists costs approximately $250,000 per year. In the combinatorial
approach, chemists were only need for 2 months.
(7) Since the marginal cost of preparing additional compounds using combinatorial
chemistry is negligible, a ten-fold increase in the number of compounds prepared
would result in a per unit cost of approximately $2.
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The hypothetical case was based on considerable experience with projects that
were comparable in complexity and degree of difficulty but were developed using the
traditional medicinal approach. A "rational" drug design approach would have
focused on reducing the number of compounds tested in the traditional approach by
maximizing the learning between successive rounds - but at considerable additional cost
and time. Thus, it is unclear whether current "rational" drug design would have
improved the efficiency and output of the traditional approach at all. The data from
table 3 shows that the combinatorial approach was not only more cost effective but also
led to a dramatically lower discovery lead time, allowing the firm to move to the clinical
phase much earlier. It also identified lead compounds that showed a high degree of
selectivity and thus much promise of success for the next development phases. In fact,
interviewees strongly felt that with the cost and time required using traditional medicinal
methods, it would have been (1) unlikely that the project had been pursued; and if
pursued, (2) nearly impossible to identify a promising lead compound with the required
selectivity.
Of course, combinatorial chemistry does not offer the same advantage for all
projects, and is currently not applicable at all to some kinds of molecules. Natural
compound chemistry deals very often with molecules of high complexity. Methods of
combinatorial chemistry are very hard to adapt to achieve specific and selective
reactions with those types of molecules. However, its area of applicability is rapidly
expanding and many companies are working on the conversion of classical organic
chemical reactions to combinatorial systems. The range of improvement currently for
projects where combinatorial chemistry is applicable may be from 10% to 80% reduction
in the cost and time devoted to lead optimization and, as was noted earlier, the
development of better quality lead compounds than is customarily accomplished by
traditional medicinal chemistry techniques.
5. Discussion
In this paper, we have argued that the economics of problem-solving and the
related R&D efficiency are being radically affected by the use of new and greatly
improved versions of methods such as computer simulation and combinatorial
chemistry. With the help of a field study of pharmaceutical drug discovery, we
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demonstrated the dramatic economic changes that can result from the adoption of such
experimental modes.
As we noted earlier, novel experimental methods such as the one we documented
in our case study can importantly affect the relative competitive position of firms if
techniques that offer such advantages are not rapidly picked up by rivals as well. It is
likely that the methods discussed in our case, combinatorial chemistry and rational drug
design, would offer significant competitive advantages to innovators and early adopters
because they are in fact difficult to transfer successfully from firm to firm. Both require
types of equipment and skills not required by what we have termed traditional drug
discovery processes. Both also require significant organizational changes, such as
changes in the interrelationships and relative importance of various specialist groups
such as medicinal chemists - who have a central role in traditional drug discovery
processes, but are less central in the case of both rational drug design and combinatorial
chemistry.
In sum, we conclude that modes of experimentation can importantly affect both
the effectiveness of firms' innovation processes and their relative competitive positions.
We therefore propose that further studies on this topic may be of interest to both
innovation researchers and innovation practitioners. Such research could show how
much of the differences in the relative effectiveness of firm innovation processes are
traceable to differences in the experimental methods employed, and the skill with which
those methods are used. It would also make clear the attributes of such methods that
convey the greatest competitive advantage. For example, it is likely that the methods
that are the hardest to transfer to new users will be the ones that offer the greatest
competitive advantagerivals to method users - while method sellers are likely to
appropriate the most benefit from methods that are easily transferred.
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Appendix
A. Proof for table 2
The Expected Number of Trials until Successfor Serial Experimentation (Minimal Learning)
Assume that the set of possible experimental trials is of size n. After each trial,
a screen tests if the completed trial is the solution (there is only one solution in n). If the
experimental trial results in a solution, the experimenter stops. If the experimental trial
is unsuccessful, the experimenter randomly selects the next experimental trial and
continuous. Since the trials are randomly selected, the experimenter only knows that
unsuccessful trials should be avoided - the experimental learning is minimal.
Our random variable of interest, denoted by X, is defined as the number of trials
required to achieve the first success. The range space for X is Rx={1,2,3,...,n}, and the
distribution of X is given by
P(x)=(I-I )X - 2 1 1 ... 1 X 1
pnx) n-l( n-2) n-x+2 n-x+l
=n-l (n-2 (n-3 n-x+l ( 1
p n n-1 n-2 n-x+2 n -x+l
1
p(x)= -
n
The expected value of this distribution can be easily found as follows:
n 1 n 1 n(n+l) n+lE[X] = xi xpi =-xxi =- Xx
i=1 n i n 2 2
Thus, the experimenter should expect to run approximately half of all possible
experimental trials before finding the solution. If learning occurs, however, and the
experimenter can intelligently select the next trial (as opposed to randomly), the
expected number of experimental trials before success will clearly be less than (n+1)/2.
_sj~~~~~rr ~~~~~ I ~I1 _ _1_____^__ __~~~~~~~~~~~~~~~- 
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B. Combinatorial Chemistry
Combinatorial chemistry is a very novel experimentation methodology and has
evolved over the last decade. It consists of several new chemical synthesis strategies for
the efficient generation of a large number of chemical compounds. This large number of
chemical compounds, also called compound libraries, is subsequently used in
pharmaceutical drug screening projects. The term "combinatorial" originates from
chemical synthesis methods applied to most of these libraries.
The following is a brief description of the main process technologies that enable a
large number of parallel experiments to be generated quickly and at low cost:
* Biochip libraries: Photolithographic synthesis methods are used for the creation of
compound libraries on the surface of a silicon chip (Fodor et. al. 1991). Up to 10,000
individual compounds can be synthesized on a silicon chip with little more than one
square centimeter surface area.
* Solid support libraries: Compounds are synthesized on the surface of polymer
beads. This method allows the chemist to attach a certain type of molecule to glass
beads and split the pool of glass beads to continue with different synthesis steps (see
example below).
* Solution libraries: Mixtures of compounds react chemically in a carefully designed
system to form solution libraries with tens to thousands of different compounds
within a few hours.
· Rapid parallel synthesis libraries: Robotic equipment is custom-tailored to dispense
chemicals into individual reaction chambers, carry out many individual chemical
reactions in parallel, and extract and purify the reaction products automatically.
Although this process is significantly slower than the other three technologies, it
results in individually purified compounds at quantities sufficiently large for
elaborate second round screening. (The other methods require chemical resynthesis
which may cause a small but significant time delay.)
To illustrate how such a combinatorial chemistry works, consider the process of
building solid support libraries. In the first synthesis phase, polymer beads are reacted
in three different reaction vessels with chemical A in vessel 1, chemical B in vessel 2 and
chemical C in vessel 3. After the reactions are completed, all the polymer beads are
pooled and mixed. The mixture is now split into three equal portions and placed in
_ _ ___I_
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vessel 1, 2 and 3. Each vessel now contains three mixtures: polymer beads covered with
A, B and C.
In the second phase, Vessel 1 is reacted with chemical D, vessel 2 is reacted with
chemical E and vessel 3 is reacted with chemical F. The result of this reaction is as
follows:
- vessel 1 contains polymer beads carrying A-D, B-D, and C-D
- vessel 2 contains polymer beads carrying A-E, B-E, and C-E
- vessel 3 contains polymer beads carrying A-F, B-F, and C-F
The output of the second synthesis phase is a diversity of 32 = 9 compounds. Without
the splitting and mixing of the polymer beads after the first synthesis round and the
combining of the individual pools, the second synthesis round would have yielded only
3 compounds. Combinatorial chemistry can increase the number of compounds by the
power of the synthesis phases, resulting in a large chemical diversity very quickly. For
instance the third round of the example given above would result in 33 = 27 compounds
(see table B.1).
Phase Vessel 1 Vessel 2 Vessel 3 N
1 A B C 3
2 A-D, B-D, C-D A-E, B-E, C-E A-F, B-F, C-F 9
3 A-D-G, B-D-G, C-D-G A-D-H, B-D-H, C-D-H A-D-I, B-D-I, C-D-I 27
A-E-G, B-E-G, C-E-G A-E-H, B-E-H, C-E-H A-E-I, B-E-I, C-E-I
A-F-G, B-F-G, C-F-G A-F-H, B-F-H, C-F-H A-F-I, B-F-I, C-F-I
k I... ... ... 3k
Table B.1. Building solid support libraries. At the beginning of each round, a new
reagent is introduced to each vessel. (For example, A is added to vessel 1 in round
1, D is added to vessel 1 in round 2, G is added to vessel 1 in round 3, etc.)
Chip technology and solution libraries are following different chemistries but
have similar exponential increases in compounds generated with each synthesis round.
Rapid parallel synthesis, however, achieves its efficiency gain through robot technology
and parallel execution of many individual reactions. However, the efficiency gain is not
exponential with the synthesis phase.
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